Intriguingly, in xenografts, the BRAF inhibitor/bosentan combination treatment led to a significant suppression of EDNRA expression within the residual tumours (Fig 6F), which correlates with the drop in AXL expression (Fig 6E). This evidence concerns the gene EDNRA and neoplasm.